Skip to main content
SpringerLink
Log in

Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background:Cancer antigen (CA) 125 tumor-associated antigen is a high molecular glycoprotein used for follow-up of epithelial ovarian cancer. The test is often requested as a differential diagnosis in patients with pleural or peritoneal fluid. This study analyzes the prevalence of CA-125 increases in a population of patients attending a general hospital and discusses the possible clinical implications of increased levels.

Methods:On 4 different days, 380 CA-125 assays were performed in randomly selected patients attending our hospital. Serum CA-125 was measured with a commercial enzyme immunoassay, and clinical records were reviewed for assessment of clinical parameters.

Results:Sixty-one patients (16%) had increased CA-125. The pathologies of these patients were heart failure in 9 (14.7%), lung disease 11 (18%), hepatic cirrhosis in 7 (11.4%), malignant tumors in 9 (14.7%), intra-abdominal nonhepatic disease in 6 (10%), previous surgery in 17 (27.8%), and miscellaneous in 2 (3%). Effusions were seen in 34 patients (55.7%).

Conclusions:Our data confirm the variety of benign and malignant pathologies coursing with increased CA-125. Cardiovascular and chronic liver disease were the most frequent diagnoses in patients with increased CA-125; this supports the opinion that CA-125 lacks utility as a marker for malignancy. CA-125 could have a role in the follow-up of cardiovascular, hepatic, and tumoral diseases with serosal involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Petignat P, Joris F, Obrist R. How CA-125 is used in routine clinical practice. Eur J Cancer 2000; 36: 1933–7.

    CAS  PubMed  Google Scholar 

  2. Bast RC, Xu FJ, Barnhill A, et al. CA-125: the past and the future. Int J Biol Markers 1998; 13: 179–87.

    CAS  PubMed  Google Scholar 

  3. Jiménez Lacave A, Allende Monclús M. Falsos negativos y positivos de los marcadores tumorales: sus limitaciones en la práctica clínica. Aplicaciones clínicas al CA-125. Rev Clin Esp 2001; 201: 715–7.

    PubMed  Google Scholar 

  4. Buamah P. Benign condition associated with raised serum CA-125 concentration. J Surg Oncol 2000; 75: 264–5.

    CAS  PubMed  Google Scholar 

  5. Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993; 1–2: 93–8.

    Google Scholar 

  6. Zeimet AG, Marth C, Offner FA, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996; 3: 384–9.

    Google Scholar 

  7. Zeimet AG, Offner FA, Marth C, et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997; 17: 3129–31.

    CAS  PubMed  Google Scholar 

  8. Nagele H, Bahlo M, Klapdor R, et al. CA-125 and its relation to cardiac function. Am Heart J 1999; 137: 1044–9.

    CAS  PubMed  Google Scholar 

  9. Ott K, Sendler A, Heidecke CD, et al. Bronchogenic cyst of the esophagus with high tumor marker levels—a case report and review of the literature. Dis Esophagus 1998; 11: 130–3.

    CAS  PubMed  Google Scholar 

  10. Yilmaz A, Ece F, Bayramgurler B, et al. The value of CA-125 in the evaluation of tuberculosis activity. Respir Med 2001; 95: 666–9.

    CAS  PubMed  Google Scholar 

  11. Bilgin T, Karabay A, Dolar E, et al. Peritoneal tuberculosis with pelvic abdominal mass, ascites and elevated CA-125 mimicking advanced ovarian carcinoma: a series of 10 cases. Int J Gynecol Cancer 2001; 11: 290–4.

    CAS  PubMed  Google Scholar 

  12. Manidakis IG, Angelakis F, Sifakis S, et al. Genital tuberculosis can present as disseminated ovarian carcinoma with ascites and raised CA-125: case report. Gynecol Obstet Invest 2001; 51: 274–6.

    Google Scholar 

  13. Mas MR, Comert B, Saglamkaya U, et al. CA-125: a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver Dis 2000; 32: 595–7.

    CAS  PubMed  Google Scholar 

  14. Kumar KS, Lee WM. Chylous ascites with marked elevation of CA-125 in cirrhosis. Am J Gastroenterol 2000; 95: 3313–4.

    CAS  PubMed  Google Scholar 

  15. Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 199; 94: 1613–8.

    CAS  PubMed  Google Scholar 

  16. Ahmed AS, Long M, Donaldson D. Lessons to be learned: a case study approach—ascites and elevated serum CA-125 due to a pancreatic carcinoma. A diagnostic dilemma. J R Soc Health 2000; 120: 47–51.

    CAS  Google Scholar 

  17. Sperti C, Pasquali C, Perasole A, et al. Macrocystic serous cystadenoma of the pancreas: clinicopathologic features in seven cases. Int J Pancreatol 2000; 28: 1–7.

    CAS  PubMed  Google Scholar 

  18. Kammerer-Doak DN, Magrina JF, Nemiro JS, et al. Benign gynecological conditions associated with a CA-125 level >1,000 U/ml. A case report. J Reprod Med 1996; 41: 179–82.

    CAS  PubMed  Google Scholar 

  19. Kashyap RJ. Extremely elevated serum CA-125 due to endometriosis. Aust N Z J Obstet Gynaecol 1999; 39: 269–70.

    CAS  PubMed  Google Scholar 

  20. But I, Reljic M. The value of serum CA-125 for the management of tubo-ovarian abscesses. Wien Klin Wochenschr 2000; 112: 1044–8.

    CAS  PubMed  Google Scholar 

  21. Migishima F, Jobo T, Hata H, et al. Uterine leiomyoma causing massive ascites and left pleural effusion with elevated CA-125: a case report. J Obstet Gynaecol Res 2000; 26: 283–7.

    Article  CAS  PubMed  Google Scholar 

  22. Tavmergen E, Sendag F, Goker EN, et al. Value of serum CA-125 concentrations as predictors of pregnancy in assisted reproduction cycles. Hum Reprod 2001; 16: 1129–34.

    CAS  PubMed  Google Scholar 

  23. Rippe B, Simonsen O, Heimburger O, et al. A. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348–57.

    CAS  PubMed  Google Scholar 

  24. Sessler R, Konyar H, Haasche G, et al. The haemodialysis patient with night sweats, ascites, and increased CA-125. Nephrol Dial Transplant 2001; 16: 175–7.

    CAS  PubMed  Google Scholar 

  25. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DJ, et al. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 17–22.

    CAS  PubMed  Google Scholar 

  26. Sari R, Camci C, Sevine A, et al. The effect of abdominal surgery on serum CA-125 levels. Clin Exp Obstet Gynecol 2000; 27: 244–5.

    CAS  PubMed  Google Scholar 

  27. Epiney M, Bertossa C, Weil A, et al. CA-125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15: 1261–5.

    CAS  PubMed  Google Scholar 

  28. Lazzarino M, Orlandi E, Klersy C, et al. Serum CA-125 is of clinical value in the staging and follow-up of patients with non-Hodgkin’s lymphoma: correlation with tumor parameters and disease activity. Cancer 1998; 82: 576–82.

    CAS  PubMed  Google Scholar 

  29. Chou SM, Anderson JS. Primary CNS malignant rhabdoid tumor (MRT): report of two cases and review of literature. Clin Neuropathol 1991; 10: 1–10.

    CAS  PubMed  Google Scholar 

  30. Watanabe M, Kanda T, Takatama M, et al. An autopsy case of malignant lymphoma with a high serum CA 125 level occurring only in the brain and pericardium. J Med 1996; 27: 221–7.

    CAS  PubMed  Google Scholar 

  31. Ohta H, Koyama R, Nagai T, et al. Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation. Int J Clin Oncol 2001; 6: 157–62.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Clínica Puerta de Hierro, Hospital Universitario, Madrid, Spain

    C. Miralles MD, PhD, P. España MD, PhD, M. Provencio MD, PhD, A. Sánchez MD, B. Cantos MD, R. Cubedo MD, E. Carcereny MD & F. Bonilla MD, PhD

  2. Servicio de Bioquímica, Clínica Puerta de Hierro, Hospital Universitario, Madrid, Spain

    M. Orea MD & T. Gea MD, PhD

  3. Servicio de Oncología Médica, Hospital Universitario Clínica Puerta de Hierro, San Martín de Porres 4, 28035, Madrid, Spain

    P. España MD, PhD

Authors
  1. C. Miralles MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Orea MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. España MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Provencio MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Sánchez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Cantos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Cubedo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Carcereny MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Bonilla MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T. Gea MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. España MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miralles, C., Orea, M., España, P. et al. Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. Ann Surg Oncol 10, 150–154 (2003). https://doi.org/10.1245/ASO.2003.05.015

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2003.05.015

Key Words:

Search

Navigation